{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:20:03Z","timestamp":1786119603082,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1097\/ico.0b013e3181e9af18","type":"journal-article","created":{"date-parts":[[2010,11,19]],"date-time":"2010-11-19T02:29:11Z","timestamp":1290133751000},"page":"260-264","source":"Crossref","is-referenced-by-count":1,"title":["Enteric-coated Mycophenolate Sodium as a Corticosteroid-sparing Agent for the Treatment of Autoimmune Scleritis"],"prefix":"10.1097","volume":"30","author":[{"given":"Yih-Shiou","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Chi Jesse","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko-Jen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-Kuo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hsi","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210204","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0161-6420(03)00570-0","article-title":"Mycophenolate mofetil for the treatment of scleritis.","volume":"110","author":"Sen","year":"2003","journal-title":"Ophthalmology"},{"key":"R2-2-20210204","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0002-9394(00)00710-8","article-title":"Episcleritis and scleritis: clinical features and treatment results.","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"R3-2-20210204","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.ophtha.2008.04.026","article-title":"Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation.","volume":"115","author":"Galor","year":"2008","journal-title":"Ophthalmology"},{"key":"R4-2-20210204","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0161-6420(90)32485-5","article-title":"Scleritis in relapsing polychondritis. Response to therapy.","volume":"97","author":"Hoang-Xaun","year":"1990","journal-title":"Ophthalmology"},{"key":"R5-2-20210204","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0161-6420(99)90078-7","article-title":"Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease.","volume":"106","author":"Larkin","year":"1999","journal-title":"Ophthalmology"},{"key":"R6-2-20210204","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00467-008-0899-6","article-title":"Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome.","volume":"23","author":"Dorresteijn","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"R7-2-20210204","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3899\/jrheum.080517","article-title":"Cost comparison between mycophenolate mofetil and cyclophosphamide-azathioprine in the treatment of lupus nephritis.","volume":"36","author":"Tse","year":"2009","journal-title":"J Rheumatol"},{"key":"R8-2-20210204","first-page":"1659","article-title":"Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis.","volume":"22","author":"Morris","year":"1990","journal-title":"Transplant Proc"},{"key":"R9-2-20210204","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/lt.21530","article-title":"Long-term outcome of mycophenolate mofetil rescue therapy for resistant acute allograft rejection in pediatric liver transplant recipients.","volume":"14","author":"Aw","year":"2008","journal-title":"Liver Transpl"},{"key":"R10-2-20210204","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/j.transproceed.2008.07.041","article-title":"Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders.","volume":"40","author":"Darji","year":"2008","journal-title":"Transplant Proc"},{"key":"R11-2-20210204","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1517\/14656566.5.6.1333","article-title":"Review of the immunosuppressant enteric-coated mycophenolate sodium.","volume":"5","author":"Budde","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"R12-2-20210204","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.2165\/0003495-200868170-00007","article-title":"Enteric-coated mycophenolate sodium: a review of its use in the prevention of renal transplant rejection.","volume":"68","author":"Sanford","year":"2008","journal-title":"Drugs"},{"key":"R13-2-20210204","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1399-3046.2007.00831.x","article-title":"Improved gastrointestinal symptom burden after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in kidney transplanted children.","volume":"12","author":"Pape","year":"2008","journal-title":"Pediatr Transplant"},{"key":"R14-2-20210204","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1046\/j.1600-6143.2003.00337.x","article-title":"Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients.","volume":"4","author":"Salvadori","year":"2004","journal-title":"Am J Transplant"},{"key":"R15-2-20210204","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1097\/01.tp.0000209411.66790.b3","article-title":"Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.","volume":"81","author":"Chan","year":"2006","journal-title":"Transplantation"},{"key":"R16-2-20210204","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3109\/09273940903137675","article-title":"Mycophenolate sodium for immunosuppressive treatment in uveitis.","volume":"17","author":"Deuter","year":"2009","journal-title":"Ocul Immunol Inflamm"},{"key":"R17-2-20210204","doi-asserted-by":"crossref","first-page":"517S","DOI":"10.1016\/j.transproceed.2004.01.052","article-title":"Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients.","volume":"36","author":"Sollinger","year":"2004","journal-title":"Transplant Proc"},{"key":"R18-2-20210204","first-page":"112","article-title":"Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patients.","volume":"66","author":"Salvadori","year":"2006","journal-title":"Clin Nephrol"},{"key":"R19-2-20210204","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.transproceed.2004.12.020","article-title":"Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.","volume":"37","author":"Massari","year":"2005","journal-title":"Transplant Proc"},{"key":"R20-2-20210204","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1432-2277.2009.00877.x","article-title":"Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation.","volume":"22","author":"Shehata","year":"2009","journal-title":"Transpl Int"},{"key":"R22-2-20210204","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1111\/j.1572-0241.2008.02161_13.x","article-title":"Mycophenolate sodium: effective treatment for therapy-refractory intestinal Behcets disease, evaluated with enteroscopy.","volume":"103","author":"Kappen","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R23-2-20210204","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/09273940902862992","article-title":"Mycophenolate mofetil therapy for sarcoidosis-associated uveitis.","volume":"17","author":"Bhat","year":"2009","journal-title":"Ocul Immunol Inflamm"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00003226-201103000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:38:00Z","timestamp":1786041480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00003226-201103000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e3181e9af18","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}